Insmed (INSM) Net Cash Flow (QoQ) (2010 - 2026)
Powered by 
Analysis
Insmed (INSM) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -151.37% |
| Mar 31, 2026 | -58.85% |
| Dec 31, 2025 | 118.52% |
| Sep 30, 2025 | -207.78% |
| Jun 30, 2025 | 676.42% |
| Mar 31, 2025 | -260.57% |
| Dec 31, 2024 | 112.08% |
| Sep 30, 2024 | -220.78% |
| Jun 30, 2024 | 470.18% |
| Mar 31, 2024 | 2,086.93% |
| Dec 31, 2023 | 95.50% |
| Sep 30, 2023 | 63.72% |
| Jun 30, 2023 | -235.51% |
| Mar 31, 2023 | -115.91% |
| Dec 31, 2022 | 20,153.04% |
| Sep 30, 2022 | 96.67% |
| Jun 30, 2022 | 50.58% |
| Mar 31, 2022 | -54.36% |
| Dec 31, 2021 | -59.44% |
| Sep 30, 2021 | -115.68% |